Энзикс дуо

Quick links to important sections

Энзикс дуо

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Энзикс дуо

What is Энзикс дуо? (Overview and Identity)

Property Description
Active ingredients Enalapril maleate, Hydrochlorothiazide
Form Oral tablet
Pharmacological class ACE Inhibitor and Thiazide Diuretic (Combination)
Common use High blood pressure (Antihypertensive)
Origin Synthetic
Rx Status Prescription Only

What Type of Medicine is Энзикс дуо?

Энзикс дуо is a prescription-only synthetic medication classified as a fixed-dose combination antihypertensive agent used to help regulate elevated blood pressure. Pharmacologically, it belongs to the dual class of Angiotensin-Converting Enzyme (ACE) Inhibitors and Thiazide Diuretics. The combination of these two established pharmacological groups provides a complementary and effective approach to managing systemic pressure, a strategy clinically recognized for its efficacy in controlling hypertension.

The product's identity as a fixed-dose combination signifies that the two distinct active components are combined in a single, convenient oral tablet. This dual mechanism is widely recognized as a standard strategy for treating essential hypertension.

Key Components and General Purpose

Энзикс дуо contains the two active ingredients: Enalapril maleate and Hydrochlorothiazide. Enalapril maleate is a prodrug that is converted by the body into the active metabolite, Enalaprilat, which provides the ACE inhibition mechanism. Hydrochlorothiazide acts as a Thiazide Diuretic, assisting in volume and fluid regulation.

The general purpose is to achieve a more comprehensive and stable reduction in high blood pressure than single-agent treatments. The combined action helps manage systemic pressure by both promoting the relaxation of blood vessels (ACE inhibitor) and supporting the reduction of overall circulating fluid volume (diuretic). This consistently controlled blood pressure helps mitigate the chronic strain of hypertension on the heart and blood vessels.

What side effects are possible with Энзикс дуо?

Possible side effects and safety information

Regulatory documents classify potential adverse reactions for Энзикс дуо (Enalapril maleate and Hydrochlorothiazide) based on frequency and the body systems affected. The officially documented safety profile ranges from commonly observed events to rare, clinically serious adverse reactions, which establish specific limitations on the medicine's use.

Common Adverse Reactions

The most frequently observed adverse reactions, as classified in official labeling, include dizziness, headache, cough, fatigue (asthenia), and hypotension (low blood pressure). The cough is specifically associated with the ACE inhibitor component (Enalapril).

System-Organ Classifications and Serious Reactions

Adverse effects are grouped by body systems, including Vascular, Nervous System, Respiratory, and Gastrointestinal disorders. The label identifies certain serious adverse reactions that require attention. These include Angioedema (swelling of the face, throat, or tongue), severe Hematological Effects such as agranulocytosis, and severe cutaneous reactions like Stevens-Johnson Syndrome.

Safety Constraints and Specific Populations

The official safety profile includes explicit constraints for certain populations and conditions. The medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Use is also restricted in patients with a history of angioedema related to previous ACE inhibitor use, and in individuals with severe hepatic or renal impairment. These official restrictions define the conditions under which the medicine should not be used.

Overdose and Emergency Response

Overdose and When to Seek Help

This information details the official, regulator-documented profile for an overdose of Энзикс дуо (Enalapril maleate and Hydrochlorothiazide).


Documented Overdose Presentations

Feature Official Regulatory Statement
Primary Manifestation Marked hypotension (severely low blood pressure) and stupor.
Associated Signs Syncope (fainting), feeling light-headed, increased thirst, and excessive diuresis.
Lab Abnormalities Electrolyte depletion, specifically hypokalemia, hyponatremia, and hypochloremia, leading to dehydration.

Severe Outcomes and Emergency Action

Overdose may lead to severe outcomes primarily due to profound hypotension. Regulatory documents cite potential risks including acute renal failure, myocardial infarction (heart attack), and cerebrovascular accident (stroke).

When to Seek Urgent Help

Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if the affected individual has collapsed, experiences trouble breathing, has a seizure, or cannot be awakened.

There is no specific antidote for this medication. Treatment is officially defined as symptomatic and supportive, which includes correcting hypotension with intravenous fluids and managing electrolyte imbalances. The active metabolite, Enalaprilat, is known to be removable by hemodialysis.

Therapeutic Uses of Энзикс дуо

What Энзикс дуо Treats: Main Uses and Benefits

The primary therapeutic domain of Энзикс дуо is the long-term management of essential arterial hypertension (high blood pressure) in adults. Managing high blood pressure may assist in mitigating the risks associated with serious cardiovascular events, such as stroke or heart attack.

The medication is commonly used to address the symptoms related to systemic imbalance by supporting the process of moderating elevated pressure readings toward a target range. It is applied across conditions marked by increased physiological stress where the elevated systemic pressure creates noticeable physiological strain.

The combination is applied across clinical settings that involve acute or unstable symptom patterns, relevant when additional symptomatic support is needed. It is used in situations where patients experience high blood pressure that is unresponsive to monotherapy. This combination may be part of symptomatic management, offering supportive relief that helps patients cope more steadily with symptom fluctuations. The medication is applied in conditions marked by increased physiological stress, relevant for easing significant symptomatic burden.


“This combination may assist with maintaining functional stability and significantly contributes to easing the overall symptom load caused by chronic high blood pressure.”


Quick Fact: Support for Systemic Strain
This combination assists with maintaining functional stability and significantly contributes to easing the overall symptom load caused by chronic high blood pressure.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official regulatory documents define eligibility for Энзикс дуо by classifying patient populations based on hypersensitivity, organ function status, and specific comorbidity restrictions. This classification determines who is permitted, restricted, or absolutely prohibited from using the fixed-dose combination.


Eligibility Scope

Category Official Regulatory Statement
Populations Allowed Adults with essential hypertension not adequately controlled by enalapril alone.
Populations Contraindicated Pregnancy (2nd and 3rd trimesters), Anuria, or Severe Renal Impairment (CrCl le 30 mL/min).
History of Angioedema related to previous ACE inhibitor use or hypersensitivity to components/sulfonamide drugs.
Use Not Established/Not Recommended Pediatric patients (under 18 years) as safety and efficacy have not been established.
Women in the first trimester of pregnancy or who are lactating.

Eligibility-Context Constraints

The medicine is also contraindicated with concomitant use of Aliskiren in patients with diabetes or renal impairment, or within 36 hours of taking a Neprilysin Inhibitor (e.g., sacubitril). Furthermore, use requires specific caution in patients with Severe Hepatic Impairment or cardiac outflow tract obstruction. This structure ensures exclusion for populations with defined life-threatening risks.

What should I know about interactions with other medicines?

The interaction profile for Энзикс дуо is officially documented based on the combined regulatory properties of its ACE inhibitor (Enalapril) and thiazide diuretic (Hydrochlorothiazide) components.

Interaction Domain Official Restriction or Outcome
Contraindicated Combinations Co-administration with Sacubitril/Valsartan is prohibited due to the officially documented risk of angioedema. A 36-hour washout period is mandatory when switching between these medications. Use with the direct renin inhibitor Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment.
Pharmacodynamic Risks Concomitant use with Lithium may result in a reversible increase in serum concentrations and toxicity due to officially noted reduced renal clearance. Use with Potassium Supplements or potassium-containing Salt Substitutes carries an officially noted risk of hyperkalemia (elevated serum potassium). Other antihypertensive agents may cause additive antihypertensive effects. Substances like mTOR Inhibitors are also associated with an increased risk of angioedema.
Exposure and Efficacy Cholestyramine and Colestipol are documented to reduce the absorption and systemic exposure of the hydrochlorothiazide component. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may diminish the intended blood pressure-lowering effect and increase the risk of deterioration of renal function, particularly in patients with pre-existing compromise. Alcohol/Ethanol may have additive effects on lowering blood pressure, increasing the risk of dizziness.

This profile establishes clear regulatory prohibitions and requirements for co-administration. Interactions with food are not officially noted to affect the absorption of the Enalapril component.

Mechanism of Action

Энзикс дуо is a fixed-dose combination product containing Perindopril and Indapamide, which modulate distinct system-level physiological control mechanisms.

Perindopril acts as a pro-drug, undergoing hepatic biotransformation to its active metabolite, Perindoprilat. Perindoprilat is a competitive inhibitor of the somatic Angiotensin-Converting Enzyme (ACE) in the circulatory system and tissue sites.

This molecular interaction prevents the conversion of Angiotensin I to the potent vasoconstrictor, Angiotensin II. Downstream consequences include a reduction in Angiotensin II plasma concentration, which mediates decreased AT1 receptor activation on vascular smooth muscle, promoting vasodilation. ACE inhibition also attenuates the degradation of Bradykinin, a vasodilator peptide, further contributing to systemic vascular relaxation. Concurrently, reduced Angiotensin II signaling diminishes the adrenal cortex's secretion of Aldosterone, decreasing sodium and water reabsorption in the distal renal tubules.

Indapamide is a thiazide-like diuretic that acts on the kidney's distal convoluted tubule. It functions as an inhibitor of the sodium-chloride co-transporter ( Na^+/ Cl^- cotransporter). This blocks the tubular reabsorption of Na^+ and Cl^-, resulting in increased delivery of these ions and water to the collecting duct and subsequent natriuresis and diuresis. This cellular process leads to a reduction in extracellular fluid and plasma volume. Furthermore, Indapamide is suggested to possess a direct effect on vascular tissue, potentially involving modulation of cellular calcium handling, which decreases vascular smooth muscle reactivity. The convergent effects of both components result in sustained systemic vascular resistance reduction and extracellular fluid volume contraction.

Dosage and Administration Information

Official Administration Guidelines for Энзикс дуо

Энзикс дуо (Enalapril maleate and Hydrochlorothiazide) is a prescription-only medication with specific usage guidelines outlined in prescribing information, focusing strictly on administration protocol rather than therapeutic outcomes.


General Usage Principles

Usage Entity Instruction
Route of Administration The medication is taken orally as a fixed-dose combination tablet.
Dosing Schedule The standard regimen is typically one tablet once daily. The maximum daily component doses are generally limited to Enalapril 20 mg and Hydrochlorothiazide 50 mg.
Intake Timing The tablet may be taken with or without food.
Use Context This fixed-dose combination is not indicated for initial therapy of essential hypertension. Its use is reserved for patients whose blood pressure is not adequately controlled with Enalapril alone, or as replacement therapy after individual component titration.

Procedural Conditions and Restrictions

Special Conditions: The combination is not recommended for use in patients with severe renal dysfunction, defined as a Creatinine Clearance (CrCl) less than 30 mL/min. Additionally, therapy with a diuretic should ideally be discontinued for 2 to 3 days before starting Энзикс дуо to mitigate a rapid change in fluid balance.

Age Restrictions: The safety and efficacy of the combination product have not been established in pediatric patients, resulting in it being generally restricted to use in adults.

The established protocol requires the patient to take the tablet orally once daily, ensuring that the necessary prerequisite conditions regarding prior treatment and kidney function are met before initiation.

Recent Clinical Evidence

Research evidence / Overview of studies for Энзикс дуо

Evidence for Use in Essential Arterial Hypertension

Research for the fixed-dose combination of Enalapril and Hydrochlorothiazide centers on randomized controlled trials (RCTs) where adults with elevated blood pressure were evaluated against individual ingredients or placebo. Research examined the measurement of blood pressure readings over defined study intervals, often ranging from four to twelve weeks.

Observations were reported where control targets were met in a higher percentage of patients receiving the combination, compared to those receiving a single agent. Research monitored outcomes related to systemic or functional imbalance.

Studies for Blood Pressure Uncontrolled by Monotherapy

The evidence base also consists of comparative controlled trials in patients whose pressure was not adequately managed by a single agent like Enalapril alone. Research explored whether using the fixed combination was associated with changes in blood pressure readings. Findings contribute to understanding how the combination was associated with the attainment of control targets in observed populations.

Long-Term Evidence and Cardiovascular Outcomes

Long-term evidence takes the form of meta-analyses and observational cohort studies, often observing patient groups for up to five years. Research has explored whether the use of drug class combinations was associated with the occurrence of serious cardiovascular events, such as heart attack or stroke. Findings describe patterns observed in the studies related to long-term outcomes.

Research in Specific Patient Groups

Studies have specifically monitored the combination’s use in certain populations, notably older adults (aged 65 and above), including those presenting with isolated systolic hypertension. However, limited information is available regarding the use of this combination in pediatric patients or in those with severe organ impairment, meaning the results apply only to the populations studied in the official research.

What Remains Unclear or Unstudied

The research base presents limitations: many initial trials had follow-up durations that were limited, and research often focused on surrogate endpoints like blood pressure drop, while long-term events were monitored in separate trials. Comparative evidence for this specific combination's long-term outcomes is limited, emphasizing that findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Энзикс дуо (FAQ)

Q: How soon does Enzix Duo usually start to work?

Official product information for the Enalapril component indicates that the blood pressure-lowering action typically begins within approximately one hour after taking the tablet. The maximum effect is usually observed four to six hours after administration.

Q: How long can I take Enzix Duo?

This medicine is described in regulatory sources as a treatment to help control chronic high blood pressure; it is not a cure. Official guidance emphasizes that use is typically long-term, and patients are advised to follow their prescribed regimen.

Q: Can Enzix Duo be used for prevention?

Regulatory documents specify that this medicine is intended for the treatment of established essential hypertension (high blood pressure) that is not adequately controlled by one agent alone. It is not indicated for use as a primary preventative measure.

Q: Can I stop taking Enzix Duo as soon as I feel better?

High blood pressure often has no noticeable symptoms. Official documents describe the importance of continuous, prescribed use to maintain consistent blood pressure control. Discontinuing the medication should only be done after consulting a healthcare professional.

Q: Are there generic versions of Enzix Duo with the same composition?

Yes, regulatory information confirms that generic versions containing the same active ingredients (Enalapril maleate and Hydrochlorothiazide) are commercially available. These products are approved as bioequivalent, meaning they meet the same standards for identity, quality, and action as the original drug.

Q: Is the use of Enzix Duo associated with weight gain?

Weight gain is not listed as one of the commonly or frequently reported side effects in the official safety documents. Uncommon adverse effects, such as gout, have been reported in some studies.

Q: Does Enzix Duo reduce the effectiveness of birth control pills?

Regulatory-aligned information for the Enalapril component suggests that it does not affect the efficacy of contraceptive pills or other types of contraception. However, some combined hormonal contraceptives may not be recommended if a patient has high blood pressure.

Q: Can Enzix Duo interact with supplements or vitamins?

Official drug interaction lists specify potential interactions with certain non-prescription items, including certain vitamins, herbal products, and particularly potassium supplements or potassium-containing salt substitutes. Official interaction warnings underscore the need for a healthcare professional to review all co-administered substances.

Q: Is a special diet needed when taking Enzix Duo?

Regulatory guidance often suggests adherence to a low-sodium meal plan as part of managing high blood pressure. Due to the drug's components, patients are generally advised to avoid salt substitutes that contain potassium, unless otherwise directed by their healthcare professional.

Q: Is Enzix Duo a hormonal drug?

No. According to official regulatory classification, the medicine is an Angiotensin-Converting Enzyme (ACE) Inhibitor combined with a Thiazide Diuretic. It works by modulating fluid volume and blood vessel constriction, and is not classified as a hormonal medication.

Q: What will happen in case of accidental overdose of Enzix Duo?

Official prescribing information indicates that the primary manifestation of an overdose is likely to be profound hypotension (extremely low blood pressure). Other potential effects include electrolyte imbalances and dehydration.

Q: Can Enzix Duo interact with grapefruit juice?

While the fixed-dose combination is not always explicitly listed, certain regulatory-aligned sources suggest limiting large amounts of grapefruit or grapefruit juice due to potential interactions with the Hydrochlorothiazide component.

Q: Can Enzix Duo affect mood or sleep?

Regulatory documents list uncommon adverse reactions that may affect the central nervous system. These include reports of insomnia, sleep disorders, depression, and confusion.

Q: What should I do if nausea starts while taking Enzix Duo?

Nausea is listed in official documents as a potential gastrointestinal side effect that occurred in approximately 3% of patients in some clinical trials. Official patient information indicates that a healthcare professional should be consulted if this or any other adverse reaction is severe or continues over time.

Q: Is there a difference in action between the original Enzix Duo and generics?

Regulatory bodies approve generic versions as being bioequivalent to the original product. This means they are required to have the same clinical effect and are identical in strength, quality, and dosage form.

Q: Why is a full course of treatment important for Enzix Duo?

Regulatory information emphasizes that the drug is designed to control high blood pressure over time and that treatment is often chronic. The necessity of continuous, prescribed use is emphasized to avoid potential complications associated with sudden uncontrolled high blood pressure.

Q: Does the effect of Enzix Duo change if taken morning or evening?

The medicine is typically prescribed to be taken once daily. Patients are generally directed to take the tablet around the same time each day to help maintain consistent blood levels, but official guidance does not designate a specific time of day for superior efficacy.

Q: What is the difference between Enzix Duo and other ACE inhibitors?

Enzix Duo is specifically a fixed-dose combination product. It contains an ACE Inhibitor (Enalapril) and a Thiazide Diuretic (Hydrochlorothiazide). Many other ACE inhibitors are single-ingredient medications (monotherapies).

How should Энзикс дуо be stored and disposed of?

How to Store and Dispose of Энзикс дуо? — Official Regulatory Information

Official government regulatory bodies have not documented explicit, publicly accessible storage, handling, or disposal requirements for the drug Энзикс дуо (Enzix Duo) in standard regulatory formats (such as FDA Prescribing Information or EMA Summary of Product Characteristics).

Since mandatory labeled instructions are not available from authoritative government sources, specific details regarding required storage temperatures, protection from environmental factors (like light or moisture), and specific shelf-life periods after opening cannot be stated.


Storage & Disposal Scope Official Statement
Labeled Storage Temperature Specific temperature ranges are not documented in government sources.
Light/Moisture Protection Requirements for environmental protection are not documented.
Official Disposal Rules Product-specific disposal instructions are not documented.
Child-Protection Storage Specific instructions to keep the product out of the reach of children are not documented.

Disposal of Unused Medicines:

In the absence of drug-specific instructions, standard regulatory guidance generally recommends using drug take-back programs at pharmacies or police stations as the preferred method for disposing of most unused or expired medicines. If a take-back option is unavailable, a product not listed as hazardous or flushable may be disposed of in household trash by mixing it with an unappealing substance like dirt or used coffee grounds and sealing it in a plastic bag before discarding. Consult a healthcare professional for the most current, product-specific instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Энзикс дуо found in:

A-Z Index: